- Allowed claims will cover the use of NeuVax alone or in combination to prevent recurrence of any breast cancer tumor expressing low-to-intermediate levels of HER2
- Extends patent coverage to three main markets, U.S., EU and now Japan
PORTLAND, Ore., Oct.
Clinical programs advance on multiple fronts, with trial initiation, trial enrollment, data and IP milestones achieved and anticipated Commercial strategy reinforced with product acquisition and upcoming commercial launch Abstral ® (fentanyl) sublingual tablet net revenue was $1.6 million in Q3 2014 and $6.1 million to date this year, with reiterated guidance of $8-$10 million for the full year 2014 Zuplenz ® (ondansetron) Oral Soluble Film U.S. rights licensed; launch expected in Q1 2015 Conference call scheduled for 5:00 pm E.T. today with details below
PORTLAND, Ore., Nov.
Sign-up for Galena Biopharma to Present GALE-301 (Folate Binding Protein) Phase 2a Clinical Trial Data at the Society for the Immunotherapy of Cancer (SITC) 29th Annual Meeting on Friday, November 7, 2014 investment picks
Sign-up for Galena Biopharma to Present GALE-401 (Anagrelide Controlled Release) Phase 1 Clinical Trial Data at the 56th American Society of Hematology (ASH) Annual Meeting & Exposition investment picks
GAMCO Investors, Inc. (NYSE:GBL) announced today that its Board of
Directors declared a special dividend of $0.25 per share in addition to
increasing its quarterly dividend by 17% to $0.07 per share to all of
its Class A and Class B shareholders, payable on December 30, 2014 to
its shareholders of record on December 16, 2014.
Game of Thrones® IMAX® Screenings Rescheduled One Week Later To Accommodate Unprecedented Fan Enthusiasm Canada NewsWire
Date Change Allows For Expanded Roll-out in IMAX® Theatres Domestically Beginning at 10 p.m. on Thursday, January 29 SANTA MONICA, Calif.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.